Quiescent psoriasis - Symptoms, Causes, Treatment & Prevention

```html

Overview

Quiescent psoriasis (also called “stable” or “inactive” psoriasis) refers to a phase of the disease in which skin lesions are present but not actively inflamed, itching, or spreading. The plaques remain thickened, scaly, and often discolored, yet the underlying inflammatory process is relatively low‑grade. This phase can last weeks to years and may alternate with flares of active disease.

Psoriasis affects roughly 2–3 % of the global population (about 125 million people). Up to 30 % of these individuals will experience periods of quiescence, especially those with plaque‑type psoriasis, the most common form (≈ 80 % of cases).

Anyone can develop quiescent psoriasis, but it is most common in adults aged 30–60, and slightly more prevalent in males than females. People of Northern European descent have the highest rates, while African and Asian populations have lower prevalence.

Symptoms

Because the disease is “quiet,” symptoms are often mild, yet patients should recognize the characteristic features:

• Well‑defined plaques – raised, erythematous (red) patches with silvery‑white scales.
• Thickness – plaques may feel leathery or thickened compared with surrounding skin.
• Color variation – lesions may be pink, red, brown, or even pale, depending on skin tone.
• Location – most common on elbows, knees, scalp, lower back, and nape of the neck; can also involve the genital area, hands, and feet.
• Itch (pruritus) – usually mild, unlike the intense itch during active flares.
• Pain or soreness – uncommon in the quiescent stage but may be present if plaques become fissured.
• Absence of new lesions – the number of plaques remains stable for months.
• Minimal or no systemic symptoms – unlike active disease, patients rarely experience fever, joint pain, or fatigue.

Causes and Risk Factors

Quiescent psoriasis is not a separate disease; it is a natural part of the psoriasis spectrum. The same genetic and environmental triggers that start active disease also influence the calm phase.

Underlying Causes

• Genetics – Over 60 susceptibility loci have been identified, the most important being HLA‑Cw6 and IL23R genes (NIH, 2022).
• Immune dysregulation – T‑helper 17 (Th17) and Th1 cells release cytokines (IL‑17, IL‑23, TNF‑α) that cause keratinocyte proliferation. In quiescent disease, cytokine levels are lower but not absent.
• Skin barrier abnormalities – Mutations in the filaggrin gene and altered lipid composition keep plaques prone to re‑activation.

Risk Factors for Developing a Quiescent Phase

• History of long‑standing plaque psoriasis.
• Effective treatment with topical steroids, vitamin D analogues, or systemic agents that suppress inflammation.
• Adherence to trigger‑avoidance strategies (e.g., stress reduction, smoking cessation).
• Older age – the immune response tends to wane over time, leading to longer quiet periods.

Diagnosis

Diagnosing quiescent psoriasis relies on clinical assessment; no special laboratory test is required, but tests help rule out other conditions.

Clinical Evaluation

1. History – duration of plaques, prior flares, treatment history, family history.
2. Physical Examination – inspection of skin for classic plaque morphology, Auspitz sign (pinpoint bleeding when scales are removed) may be absent.

Ancillary Tests (when needed)

• Skin biopsy – 4‑mm punch biopsy showing hyperkeratosis, parakeratosis, and elongated rete ridges confirms psoriasis if diagnosis is uncertain.
• Blood work – CBC, liver/kidney panels, and lipid profile if the patient is on systemic therapy; CRP or ESR may be mildly elevated even in quiescence.
• Psoriasis Area and Severity Index (PASI) – often low (≤ 5) during quiet phases, useful for monitoring treatment response.

Treatment Options

Even in a quiet phase, patients often need ongoing therapy to keep lesions from flaring and to improve skin appearance.

Topical Therapies

• Vitamin D analogues (calcipotriene, calcitriol) – normalize keratinocyte growth; safe for long‑term use.
• Low‑potency corticosteroids (hydrocortisone 1 %) – used intermittently to reduce mild scaling.
• Combination products – calcipotriene + betamethasone dipropionate offers synergistic effect with reduced steroid exposure.
• Coal‑tar preparations – useful for scalp involvement.

Systemic & Biologic Agents (maintenance)

Patients with extensive or resistant plaques may stay on low‑dose systemic agents even when quiescent:

• Methotrexate – 7.5–15 mg weekly; monitor liver function.
• Acitretin – 25 mg daily; useful for thick plaques.
• Biologics targeting IL‑17 (secukinumab, ixekizumab) or IL‑23 (guselkumab, tildrakizumab) – maintain low PASI scores and reduce flare frequency.

Procedural Options

• Phototherapy (narrow‑band UVB) – 2–3 sessions weekly for 12–16 weeks can consolidate remission.
• Laser therapy (308‑nm excimer laser) – spot‑treats stubborn plaques.

Lifestyle & Adjunct Measures

• Moisturize twice daily with thick, fragrance‑free emollients (e.g., petrolatum, ceramide creams).
• Use gentle, non‑scratching cleansing agents; avoid hot water.
• Maintain a healthy weight – obesity increases IL‑17 levels and risk of flare (CDC, 2023).
• Stress‑management techniques (mindfulness, yoga) can keep the immune response subdued.

Living with Quiescent Psoriasis

Even when the disease is “quiet,” the skin changes can affect quality of life. Below are practical tips.

• Skin care routine – Apply moisturizers within three minutes of bathing to lock in moisture.
• Clothing choices – Soft, breathable fabrics (cotton, bamboo) reduce friction and scaling.
• Sun protection – Limited UV exposure can improve plaques, but over‑exposure raises skin‑cancer risk. Use SPF 30+ broad‑spectrum sunscreen.
• Regular follow‑up – Schedule dermatologist visits every 6–12 months even when asymptomatic.
• Tracking tools – Smartphone apps (e.g., Psoriasis Tracker) help notice subtle changes before a flare.
• Psychosocial support – Join support groups or counseling; studies show a 20 % reduction in depression scores when patients engage in peer support (Cleveland Clinic, 2021).

Prevention

While you cannot prevent psoriasis entirely, you can lower the likelihood of re‑activation:

1. Maintain a healthy weight – each 5‑kg increase raises flare risk by ~10 %.
2. Quit smoking – smokers have a 1.5‑fold higher chance of severe disease.
3. Limit alcohol consumption – excessive intake can trigger cytokine spikes.
4. Identify personal triggers – stress, infections, certain medications (beta‑blockers, lithium).
5. Adhere to prescribed therapy – intermittent discontinuation often leads to rapid relapse.
6. Skin protection – avoid cuts, harsh chemicals, and prolonged pressure on plaques.

Complications

If quiescent psoriasis is left unmanaged, several complications can arise:

• Pseudo‑guttate psoriasis – sudden eruption of small, droplet‑like lesions triggered by infection.
• Psoriatic arthritis – up to 30 % of psoriasis patients develop joint disease; early signs include morning stiffness and swollen digits.
• Skin infections – fissured plaques can become portals for bacterial (Staphylococcus aureus) or fungal (Candida) infection.
• Cardiometabolic disease – chronic low‑grade inflammation raises risk of hypertension, dyslipidemia, and type 2 diabetes (American Heart Association, 2022).
• Psychological impact – persistent visible plaques can cause anxiety, depression, and social isolation.
• Skin cancer – long‑term phototherapy or immunosuppressive drugs modestly increase non‑melanoma skin‑cancer risk; regular skin exams are advised.

When to Seek Emergency Care

---

Sources: Mayo Clinic, CDC, NIH, WHO, Cleveland Clinic, American Heart Association, peer‑reviewed dermatology journals (JAMA Dermatology, British Journal of Dermatology) – accessed May 2026.

```